Regentys™ is a development stage, regenerative medicine company focused on developing treatments for patients with gastrointestinal (GI) disorders.
Regentys (formerly Asana Medical, Inc.) is a regenerative medicine company developing a tissue engineered therapy for the treatment of Ulcerative Colitis (UC). The Company's product ECMH, a novel application of a proven technology, will be a first-in-class therapy for patients suffering from Ulcerative Colitis. This therapy will be positioned to compete in a multi-billion-dollar market dominated by biologic and drug therapies that can have significant side effects. Additionally, 20-30% of patients do not benefit from these therapies and have no alternative except colon removal surgery. Regentys has an experienced management team, strong patent protection, world-class advisors in business and medicine, and compelling preclinical proof-of-concept data. For more information, visit www.regentys.com.
We are a development stage regenerative medicine company whose mission is to develop novel applications of extracellular matrix to treat IBD, such as Ulcerative Colitis and Crohn's Disease, and put patients suffering from the disease into deep remission.
Regentys (formerly Asana Medical, Inc.) is a regenerative medicine company developing a tissue engineered therapy for the treatment of Ulcerative Colitis (UC). The Company's product ECMH, a novel application of a proven technology, will be a first-in-class therapy for patients suffering from Ulcerative Colitis. This therapy will be positioned to compete in a multi-billion-dollar market dominated by biologic and drug therapies that can have significant side effects. Additionally, 20-30% of patients do not benefit from these therapies and have no alternative except colon removal surgery. Regentys has an experienced management team, strong patent protection, world-class advisors in business and medicine, and compelling preclinical proof-of-concept data. For more information, visit www.regentys.com.
